128 related articles for article (PubMed ID: 35716310)
1. Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.
Werner JM; Wolf L; Tscherpel C; Bauer EK; Wollring M; Ceccon G; Deckert M; Brunn A; Pappesch R; Goldbrunner R; Fink GR; Galldiks N
J Neurooncol; 2022 Sep; 159(2):309-317. PubMed ID: 35716310
[TBL] [Abstract][Full Text] [Related]
2. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G
ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
4. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
Rudà R; Bruno F; Pellerino A; Pronello E; Palmiero R; Bertero L; Crasto S; Polo V; Vitaliani R; Trincia E; Internò V; Porta C; Soffietti R
J Neurooncol; 2022 Nov; 160(2):389-402. PubMed ID: 36309895
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib in patients with recurrent high-grade astrocytoma.
Kebir S; Rauschenbach L; Radbruch A; Lazaridis L; Schmidt T; Stoppek AK; Pierscianek D; Stuschke M; Forsting M; Sure U; Keyvani K; Kleinschnitz C; Scheffler B; Glas M
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1037-1042. PubMed ID: 30820715
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
7. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
Kim RD; Sanoff HK; Poklepovic AS; Soares H; Kim J; Lyu J; Liu Y; Nixon AB; Kim DW
Cancer; 2020 Aug; 126(15):3464-3470. PubMed ID: 32453456
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.
Treiber H; von der Brelie C; Malinova V; Mielke D; Rohde V; Chapuy CI
Neurosurg Rev; 2022 Oct; 45(5):3201-3208. PubMed ID: 35725846
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study.
Lombardi G; Caccese M; Padovan M; Cerretti G; Pintacuda G; Manara R; Di Sarra F; Zagonel V
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572958
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
11. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
Lombardi G; Del Bianco P; Brandes AA; Eoli M; Rudà R; Ibrahim T; Lolli I; Rizzato S; Daniele B; Pace A; Pasqualetti F; Caccesse M; Bergo E; Magni G; De Salvo GL; Zagonel V
Eur J Cancer; 2021 Sep; 155():179-190. PubMed ID: 34388515
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
Zeiner PS; Kinzig M; Divé I; Maurer GD; Filipski K; Harter PN; Senft C; Bähr O; Hattingen E; Steinbach JP; Sörgel F; Voss M; Steidl E; Ronellenfitsch MW
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766326
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
[No Abstract] [Full Text] [Related]
17. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
18. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
Indraccolo S; De Salvo GL; Verza M; Caccese M; Esposito G; Piga I; Del Bianco P; Pizzi M; Gardiman MP; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Zagonel V; Lombardi G
Clin Cancer Res; 2020 Sep; 26(17):4478-4484. PubMed ID: 32518098
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
